NCT06883526View on ClinicalTrials.gov

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

May 31, 2027

Conditions
Lymphoma
Interventions
BIOLOGICAL

ZG005 for Injection

intravenous infusion

DRUG

Gecacitinib Hydrochloride Tablets

Oral

Trial Locations (1)

Unknown

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY